SMARCA1 and cancer: Furthermore, we proposed the following molecular mechanism underlying synthetic lethality induced by simultaneous inhibition of CBP/p300 in SMARCB1-deficient cancers: in SMARCB1-proficient cells, the SWI/SNF complex containing SMARCB1 represses transcription of KREMEN2.